← Leaderboards
Graham Simmons
Vitalant
$8,136,951
Attributed
$8,136,951
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $672.7K · FY2008–23$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$8,136,951 · 7
By mechanism
R01$6,336,803 · 3
R21$1,363,735 · 3
R56$436,413 · 1
Top collaborators
No co-investigators on record.
Most similar at Vitalant
Same institution · by research overlap
- Suganya Selvarajah$356,188
- Marion Lanteri$469,641
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralVirusInfectionMediatingGlycoproteinsCellsEventVirus DiseasesResponseTransmission ProcessLeadDisease OutbreaksScreeningEpidemicImmuneBaseAcuteInhibitor/AntagonistVaccinesPreventPeptide HydrolasesProphylacticSurfaceProteolysis
Grant awards (20)
Transfusion-related immunomodulation influences infectious disease outcomes$623,056
R01 · FY2023 · HL · contact PI
Transfusion-related immunomodulation influences infectious disease outcomes$615,838
R01 · FY2022 · HL · contact PI
Transfusion-related immunomodulation influences infectious disease outcomes$612,357
R01 · FY2021 · HL · contact PI
Transfusion-related immunomodulation influences infectious disease outcomes$604,784
R01 · FY2020 · HL · contact PI
Protective B-cell responses in chikungunya virus infection$450,038
R01 · FY2019 · AI · contact PI
Protective B-cell responses in chikungunya virus infection$559,024
R01 · FY2018 · AI · contact PI
Protective B-cell responses in chikungunya virus infection$510,584
R01 · FY2017 · AI · contact PI
Protective B-cell responses in chikungunya virus infection$334,094
R01 · FY2016 · AI · contact PI
Protective B-cell responses in chikungunya virus infection$436,413
R56 · FY2015 · AI · contact PI
Serological prevalence of viral hemorrhagic fevers in Equatorial Africa$191,500
R21 · FY2015 · AI · contact PI
Serological prevalence of viral hemorrhagic fevers in Equatorial Africa$246,500
R21 · FY2014 · AI · contact PI
Broad spectrum antivirals targeting envelope proteolysis and viral uncoating$221,500
R21 · FY2014 · AI · contact PI
Broad spectrum antivirals targeting envelope proteolysis and viral uncoating$277,535
R21 · FY2013 · AI · contact PI
Modeling viral entry and its inhibition using SARS-CoV$395,225
R01 · FY2012 · AI · contact PI
Optimization of XMRV and other MLV-related virus detection for screening of blood$149,200
R21 · FY2012 · HL · contact PI
Modeling viral entry and its inhibition using SARS-CoV$395,225
R01 · FY2011 · AI · contact PI
Optimization of XMRV and other MLV-related virus detection for screening of blood$277,500
R21 · FY2011 · HL · contact PI
Modeling viral entry and its inhibition using SARS-CoV$430,078
R01 · FY2010 · AI · contact PI
Modeling viral entry and its inhibition using SARS-CoV$403,250
R01 · FY2009 · AI · contact PI
Modeling viral entry and its inhibition using SARS-CoV$403,250
R01 · FY2008 · AI · contact PI